Complete Genomics

Complete Genomics is an emerging California company which has developed a third-generation genome sequencing technology that will provide complete human genetic data at a much lower cost and at a higher throughput than existing approaches.

Applying a strikingly different approach than other sequencing vendors, who are selling instruments to the scientific community, Complete Genomics offers human genome sequencing and data analysis through its own commercial-scale genome center. Customers supply the genomic DNA samples, and Complete Genomics sequences, analyzes and provides the data back in a convenient complete genome report. This will allow pharmaceutical, biotechnology and other medical research customers, for the first time, to spend more time conducting experiments and analyzing data from large-scale human genome studies for a wide variety of diagnostic and discovery applications, including clinical trials, rather than instrument runs. These more efficient studies will further elucidate the genetic underpinnings of complex diseases and drug responses, and lead to improved human health.

Because Complete Genomics is using a highly optimized and scalable technology, it is able to offer a lower price point, allowing its customers to conduct large-scale, complete human genome studies. Complete Genomics will harness the intrinsic miniaturization and parallelization potential of its DNA nanoarray-based genome sequencing system, economies of scale, and sophisticated manufacturing techniques to reduce its technology costs in proportion to the volume of genomes sequenced.

Through its efficient, information-based business model, Complete Genomics will provide customers with access to high-quality, low-cost human DNA sequencing data with no capital expenditure. Customers will no longer need to dedicate resources to prepare samples and operate sequencing instruments, nor invest in the considerable computing resources required to manage and analyze the substantial data generated. Thus, customers will be able to focus on doing science rather than on running sequencing experiments.

Complete Genomics’ combined technology and information-based business model will, for the first time, enable large-scale human genomic population studies thereby providing the basis for meaningful individual genomic analysis. Only when genomic data is gathered and analyzed on this scale will knowledge of one’s own genome be of use in disease prevention and management.